Pfizer & BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success In First Interim Analysis From Phase 3 Study

Pfizer Inc. and BioNTech SE announced that their mRNA-based vaccine candidate, BNT162b2, against coronavirus disease 2019 (COVID-19) has achieved success in its first interim analysis from a Phase 3 clinical study. Specifically, BNT162b2 demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in . . .